-
CD Moderators: someguyontheinternet
The Big & Dandy Synthetic Cannabinoids Thread
- Thread starter e1evene1even
- Start date
- Status
This is a synthetic cannabinoid as well as the others you posted, so this will be merged into the big thread for it as well.
Next time, at least search the most basic info about the RC on the net, if a cannabinoid go to this here thread please.
Everything you have posted about, especially meaning those new threads, its all included in this topic!
Where did you find that AM-694 is toxic? Please quote your source or give a link so that we may comment.
Next time, at least search the most basic info about the RC on the net, if a cannabinoid go to this here thread please.
Everything you have posted about, especially meaning those new threads, its all included in this topic!
Where did you find that AM-694 is toxic? Please quote your source or give a link so that we may comment.
If you read that the rest of that thread... OP thinks it would have toxic metabolites, then other posters explain why it it wouldn't produce that toxic metabolite, with cited evidence.
Thanks for explaining its just English is not my first language so dont understand everything 100 right
It's a synthetic cannabinoid developed by Bayer and currently in Phase II trials as a treatment for traumatic brain injury.
I am unaware of it being used recreationally.
The only cannabinoids that are available on the RC market seem to be the JWH series, CP 55,940, CP 47,497 (and the C8 homolog), and rarely WIN-55,212-2. HU-210 and 211 were available previously in some spice blends but were scheduled in many places.
All these other ones havn't made it onto the RC scene, and so nobody knows much about them.
egor
Bluelighter
^there are at least a few others...
Coolio
Greenlighter
- Joined
- Feb 29, 2004
- Messages
- 6,946
Plenty of people know about BAY 38-7271. It's in Phase II trials in the Germany, it's being developed by KeyNeurotek Pharmaceuticals.
Here's some info on it from them: http://www.keyneurotek.de/englisch/pdf/Ende Phase I Stroke_ en_final.pdf
BiG StroOnZ
Bluelighter
Can someone give me detailed information on JWH-015 or we don't know of any human guinea pigs yet? Anyway, what if one was able to get their hands on the compound? Could anyone provide some insight?
egor
Bluelighter
^(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone.
From what I understand it is far less potent than other JWH compounds but I know of no assays as of now; though I would expect to see that change in the not too distant future...
From what I understand it is far less potent than other JWH compounds but I know of no assays as of now; though I would expect to see that change in the not too distant future...
Gad Anyonya
Greenlighter
- Joined
- Jan 18, 2010
- Messages
- 5
It Looks like JWH is illegal in Canada too now, and not just JWH-018 but all types. I got 3g of a 073/081/250 blend just after the holidays, and really enjoy it in weighed 5mg hits with the oilpipe like Coolio mentions. It compares favourably to my Vapir 1/ Durban Poison combo, but doesn't last quite as long although the buzz is nice. I was planning on stocking up on more JWH as I was getting a bit paranoid with my mj arrangements. Unfortunately by the time I got the pipe and knew how good this JWH was, the ban kicked in.
I can bide my time, but I'm also hoping to see some new synthetics out there. I'll stay tuned for sure and will look into some of the new ones mentioned.
I can bide my time, but I'm also hoping to see some new synthetics out there. I'll stay tuned for sure and will look into some of the new ones mentioned.
BiG StroOnZ
Bluelighter
I want to try it out, but first I am wondering if you or anyone else had any idea on what compound the effects might be closest to (based on these):
073 - 018 - 200 - CP47,497- WIN,55212-2
?
Also what threshold dosages are we looking at?
greenmeanies
Bluelighter
- Joined
- Oct 8, 2009
- Messages
- 1,613
just tried out JWH-018 yesterday, after several years of daily high grade cannabis smoking.
vaped off foil, this compound has a strange taste, somewhat like rubber. thankfully the taste does not linger at all.
took about 15-20 minutes for effects, the first of which was a desire to smoke a bowl of real stinky weed. but i wanted to know what it was like on its own, so i held out for an hour and vaped some more jwh off foil. got pleasantly high, an energetic heady buzz, very talkative.
combination with a bowl of weed later on got me much higher than i usually get, and very little couchlock. could not stop laughing.
will test its oral response later
vaped off foil, this compound has a strange taste, somewhat like rubber. thankfully the taste does not linger at all.
took about 15-20 minutes for effects, the first of which was a desire to smoke a bowl of real stinky weed. but i wanted to know what it was like on its own, so i held out for an hour and vaped some more jwh off foil. got pleasantly high, an energetic heady buzz, very talkative.
combination with a bowl of weed later on got me much higher than i usually get, and very little couchlock. could not stop laughing.
will test its oral response later
BiG StroOnZ
Bluelighter
I've discovered a list of so many Cannabinoids you wouldn't even believe it:
1,3-bis(4-Bromophenyl)-5-phenyl-2,4-imidazolidinedione
Potent and selective inverse agonist of CB1 receptor (Ki=243nM and EC50=195nM).
Catalog # CAS Formula Unit
sc-202872 878533-35-8 C21H14Br2N2O2 5 mg
2-(14,15-Epoxyeicosatrienoyl) Glycerol
An endogenous central cannabinoid (CB1) receptor agonist that is present at relatively high levels in the central nervous system.1,2,3 2-AG is hydrolyzed by the enzyme monoacylglycerol lipase, terminating its biological activity, and metabolism by cyclooxygenase-2 and lipoxygenases has been documented.4,5 The related endocannabinoid, 2-arachidonoyl ethanolamide (AEA), can be metabolized by cytochrome P450 (CYP450) enzymes in human kidney and liver to a number of epoxy-ethanolamide derivatives.6 2-14,15-EG is a novel CYP450 metabolite of 2-AG in the kidney.7 2-14,15-EG is a potent mitogen for renal epithelial cells, increasing DNA synthesis in LLCPKcl4 cells at concentrations as low as 100 nM and doubling cell proliferation rates at 1 µM.7 In these cells, 2-14,15-EG activates the metalloprotease ADAM17, which cleaves proTGF-α and releases TGF-α as a ligand that initiates the EGFR-ERK signalling pathway.
Catalog # CAS Formula Unit
sc-205073 848667-56-1 C23H38O5 25 µg/50 µg
2-Arachidonoylglycerol (2-AG)
May contain up to 20% of the isomer 1-arachidonoylglycerol. 2-AG is the intrinsic physiological ligand for the cannabinoid CB1 receptor.
Catalog # CAS Formula Unit
sc-200794 53847-30-6 C23H38O4 5 mg
2-Palmitoylglycerol
Endogenous fatty acid glycerol ester that enhances activity of 2-arachidonylglycerol. Does not bind to CB1 or CB2 cannabinoid receptors, but potentiates the apparent binding of 2-AG and increases its ability to inhibit adenylyl cyclase. Enhances in vivo cannabinoid effects of 2-AG following combined administration with 2-linoleoylglycerol.
Catalog # CAS Formula Unit
sc-203465 23470-00-0 C19H38O4 10 mg
3-decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone
A reversible competitive inhibitor of FAAH activity exhibiting an IC50 value of 1.3 µM.2 Has no affinity for the human CB1 receptor and acts as a competitive inhibitor of FAAH activity without being hydrolyzed by the enzyme.2
Catalog # CAS Formula Unit
sc-204619 875014-22-5 C25H32N2OS 500 µg/1 mg
5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-rel-phenol
This chemical is a bicyclic cannabinoid analog that avidly binds the central cannabinoid receptor CB2 (Ki = 0.83 nM) and shows high antinociceptive activity It is ten-fold more potent than Δ9-tetrahydrocannabinol in motor depressant, analgesic, anticonvulsant, and hypothermic effects in mice.
Catalog # CAS Formula Unit
sc-223681 70434-92-3 C22H36O2 5 mg/10 mg
8-iso Prostaglandin F2α Ethanolamide
Its been reported that anandamide (AEA) can be used directly by cyclooxygenase-2 and specific prostaglandin H2 (PGH2) isomerases to produce ethanolamide congeners of the classical PGs, including PGF2α. PGF2α ethanolamide has also been reported to be biosynthesized by this mechanism when AEA was infused into the lung and liver of fatty acid amide hydrolase-deficient mice. The accumulation of AEA can also lead to isoprostane-type peroxidative decomposition. 8-iso PGF2α ethanolamide is a standard that allows one to distinguish these non-enzymatic decomposition products from “prostamides” that possible have enzymatic origin.
Catalog # CAS Formula Unit
sc-221140 N/A C22H39NO5 100 µg/500 µg
ABN-CBD
Neurobehaviorally inactive cannabinoid that acts as a selective agonist for GPR55 (EC50 values are 2.5, >30 and >30 μM at GPR55, CB1 and CB2 receptors respectively). Increases the phosphorylation of protein kinases in, and migration of, human umbilical vein endothelial cells.
Catalog # CAS Formula Unit
sc-203488 22972-55-0 C21H30O2 10 mg
Abnormal Cannabidiol-d3
Contains three deuterium atoms at the terminal methyl position. Intended for use as an internal standard for the quantification of compound by GC- or LC-mass spectrometry. A synthetic regioisomer of cannabidiol that fails to elicit either CB1 or CB2 responsiveness and is without psychotropic activity. Induces endothelium-dependent vasodilation via a CB1/CB2/nitric oxide-independent mechanism.2 Showed hypotensive activity that could not be antagonized by cannabidiol or SR141716A. Compound is therefore believed to activate a third type of CB receptor, provisionally called the non-CB1/CB2 endocannabinoid receptor. Also acts via these receptors to regulate the migratory activity of murine BV-2 microglial cells, with an EC50 value of 600 nM.3
Catalog # CAS Formula Unit
sc-223766 N/A C21H30D3O2 100 µg/500 µg
ACEA
Potent and highly selective CB1 receptor agonist. Displays > 1400-fold selectivity over CB2 receptors. Active in vivo.
Catalog # CAS Formula Unit
sc-202902 220556-69-4 C22H36ClNO 5 mg
Allopregnanolone
Progesterone metabolite devoid of any progestational activity. Acts as a potent ligand of GABA-mediated Cl uptake in synaptosomes more effectively (100- to 1,000-fold) than benzodiazepines or barbituates. In dose-dependent manner, causes a raid increase in Ca2+ influx.
Catalog # CAS Formula Unit
sc-203813 516-54-1 C21H34O2 10 mg
α-Linolenoyl Ethanolamide
α-Linolenoyl ethanolamide is an endocannabinoid containing α-linolenic acid in place of the arachidonate moiety of AEA. It has been detected in porcine brain, but its relative importance and specific role as a cannabinergic neurotransmitter have not been elucidated.
Catalog # CAS Formula Unit
sc-223763 57086-93-8 C20H35NO2 5 mg/10 mg
AM 1241
This is a potent and selective CB2 receptor agonist (Ki=3.4nM (mouse), Ki=280nM (rat) also in vivo.
Catalog # CAS Formula Unit
sc-221241 N/A C22H22N3O3I 1 mg/5 mg
AM 281
Analog of the cannabinoid receptor (CB) antagonist SR 141716A. Potent CB1 receptor antagonist/inverse agonist (Ki=14nM).
Catalog # CAS Formula Unit
sc-202050 202463-68-1 C21H19Cl2IN4O2 1 mg/5 mg
AM-251
Cannabinoid CB1 receptor antagonist (Ki=7.5 nM). Displays a high level of selectivity (306-fold) for CB1 over CB2 receptors.
Catalog # CAS Formula Unit
sc-200366 183232-66-8 C22H21Cl2IN4O 10 mg
AM-404
Anandamide transport inhibitor (IC50=1 µM). Does not activate cannabinoid receptors or inhibit anandamide amidase.
Catalog # CAS Formula Unit
sc-200363 198022-70-7 C26H37NO2 10 mg/50 mg
AM-630
Acts as a cannabinoid receptor antagonist in mouse brain, vas deferens and guinea pig brain, but an agonist in guinea pig ileum. Acts as an inverse agonist on cloned human CB1 receptors.
Catalog # CAS Formula Unit
sc-200365 164178-33-0 C23H25IN2O3 10 mg
AM1241
A peripheral cannabinoid (CB2) receptor agonist with a Ki value of 2 nM and a greater than 100-fold selectivity over the central cannabinoid (CB1) receptor in vitro.1 This molecule produces antinociception to thermal stimuli in rat hindpaw. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630 but not by the CB1 receptor-selective antagonist AM251.1
Catalog # CAS Formula Unit
sc-221242 N/A N/A 1 mg/5 mg
Anandamide (18:2, n-6)
Anandamide analog.1
Catalog # CAS Formula Unit
sc-205592 N/A C20H37NO2 5 mg/25 mg
Anandamide (20:3, n-6)
Endogenous cannabinoid ligand1. Inhibits the binding of [3H]HU-243 to synaptosomal membranes (Ki=53 nM)2.
Catalog # CAS Formula Unit
sc-205593 N/A C22H39NO2 5 mg/25 mg
Anandamide (22:4, n-6)
This compound is an endogenous cannabinoid ligand, 1,2 which inhibits the binding of [3H]HU-243 to synaptosomal membranes (Ki=34 nM)2.
Catalog # CAS Formula Unit
sc-221252 N/A N/A 5 mg/25 mg
Arachidonamide (20:4, n-6)
A weak cannabinoid CB1 and CB2 agonist 1.
Catalog # CAS Formula Unit
sc-221258 N/A N/A 10 mg/50 mg
Arachidonoyl 2'-fluoroethylamide
CB1 receptor agonist (CB1: Ki=26.7nM; CB2: Ki=908nM).
Catalog # CAS Formula Unit
sc-202469 166100-37-4 C22H36NOF 5 mg
Arachidonoyl Ethanolamide Phosphate
Since its isolation and characterization, a number of related endocannabinoids have been isolated, among them 2-arachidonoyl glycerol (2-AG).2 The phosphate ester of AEA, AEA-P, has been tested as a water soluble prodrug version of AEA in the treatment of C6 glioma cells in vivo, acting with essentially the same potency as AEA.3 However, when tested for inhibition of AEA binding to isolated rat brain CB1 receptors, AEA-P is about 5-fold less potent as an agonist.4 The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA) but the effects of AEA-P on the various LPA receptors have not been tested.
Catalog # CAS Formula Unit
sc-205210 183323-26-4 C22H38NO5P 250 µg/1 mg
Arachidonoyl Ethanolamide-d4
Contains four deuterium atoms at the hydroxyethyl 1,1',2, and 2' positions. Used as an internal standard for the quantification of AEA by GC- or LC-mass spectrometry.
Catalog # CAS Formula Unit
sc-221262 N/A C22H33D4NO2 500 µg/1 mg
Arachidonoyl p-Nitroaniline
One of many nitroaniline fatty acid amides used to measure FAAH activity. 1 This is a relatively unselective enzyme that accepts a variety of amide head groups other than the ethanolamine of its nominal endogenous substrate AEA. Has also been shown to hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Has the potential for fast and convenient measurement of FAAH activity using a 96-well plate spectrophotometer: exposure of ApNA to FAAH activity results in the release of p-nitroaniline.
Catalog # CAS Formula Unit
sc-205211 119520-58-0 C26H36N2O3 1 g/10 g
Arachidonoyl-1-thio-Glycerol
2-Arachidonoyl glycerol (2-AG) is an endogenous agonist of the central cannabinoid (CB1) receptor.1,2 It is present at relatively high levels in the central nervous system and is the most abundant molecular species of monoacylglycerol found in rat brain.2,3 Monoacylglycerol lipase (MGL) hydrolyzes 2-AG to arachidonic acid and glycerol, thereby terminating its biological actions.4 Arachidonoyl-1-thio-glycerol is a thioester substrate analog of 2-AG that can be utilized for the measurement of MGL activity.5 Hydrolysis of the thioester bond by MGL generates a free thiol that reacts rapidly with the chromogenic reagent DTNB (Ellman’s reagent) resulting a yellow product with an absorbance maximum at 412 nm.
Catalog # CAS Formula Unit
sc-221265 N/A C23H38O3S 1 mg/5 mg
Arachidonoyl-AMC
A fluorogenic substrate for fatty acid amide hydrolase (FAAH)1. This substrate is the basis for a simple, selective and sensitive assay for FAAH which is amenable to high-throughput screening.
Catalog # CAS Formula Unit
sc-223784 N/A N/A 5 mg/25 mg
Arachidonoyl-N-methyl amide
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. This compound is an analog of AEA that binds to the human CB1 receptor with a Ki of 60 nM.1 It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 µM.2
Catalog # CAS Formula Unit
sc-205212 156910-29-1 C21H35NO 5 mg/10 mg
Arachidonylcyclopropylamide (ACPA)
High affinity selective agonist for the cannbinoid CB1 receptor. Inhibits forskolin-induced cAMP accumulation, increases binding of GTPγS to cerebellar membranes.
Catalog # CAS Formula Unit
sc-200795 229021-64-1 C23H37NO 10 mg/50 mg
AVE-1625
The central cannabinoid (CB1) receptor is a G protein-coupled receptor that is widespread in the central nervous system and several peripheral tissues and binds the active component of cannabis, Δ9-tetrahydrocannabinol. Signaling through the CB1 receptor is involved in attentional and working memory deficits as well as obesity. AVE-1625 is a selective, highly potent antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM. At 1-3 mg/kg, AVE-1625 significantly enhances the performance of rodents in working memory tasks. At 30 mg/kg, AVE-1625 reduces caloric intake by more than 50% of controls, reduces hepatic glycogen levels in rodents and significantly increases lipolysis from fat tissues.
Catalog # CAS Formula Unit
sc-221277 358970-97-5 C23H20Cl2F2N2O2S 1 mg/5 mg
BML-190
A selective and potent ligand for the human cannabinoid CB2 receptor, it acts as an inverse agonist. Inhibits LPS-induced COX2 induction and LPS-induced monocytic cell neurotoxicity.
Catalog # CAS Formula Unit
sc-203533 2854-32-2 C23H23ClN2O4 10 mg/50 mg
CAY10448
An iodinated nonivamide, a potent capsaicin receptor antagonist with an IC50 of approximately 10 nM.3
Catalog # CAS Formula Unit
sc-223862 N/A C18H28INO3 1 mg/5 mg
CB 13
Potent, orally active CB1/CB2 receptor agonist with limited brain penetration (EC50 values are 6.1 and 27.9 nM for CB1 and CB2 receptors respectively). Displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects.
Catalog # CAS Formula Unit
sc-203870 432047-72-8 C26H24O2 10 mg/50 mg
CB-25
CB-25 is a stable analog of anandamide (AEA) and Δ9-tetrahydrocannabinol (THC). It exhibits high affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with Ki values of 5.2 and 13 nM, respectively. CB-25 behaves as an inverse agonist for the CB1 receptor as assessed in a cyclic AMP (cAMP) functional assay.1,2
Catalog # CAS Formula Unit
sc-204675 869376-63-6 C25H41NO3 1 mg/5 mg
CB-52
A stable analog of Δ9-tetrahydrocannabinol (THC) and anandamide (AEA) which exhibits high affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptor with Ki values of 210 and 30 nM, respectively.1 This compound behaves primarily as a CB1 receptor partial agonist and a CB2 receptor neutral antagonist in vitro.2
Catalog # CAS Formula Unit
sc-221404 N/A C26H43NO3 1 mg/5 mg
CBDD
Non-heme iron-containing dioxygenases that catalyze the oxidation of polyunsaturated fatty acids, generating unsaturated fatty acid hyperoxides1, with immediate products of 15-LO fatty acid oxidation acting as mediators in inflammation, thrombosis, and cancer.2 CBDD is a cannabidiol derivative that both potently and selectively inhibits 15-LO.3
Catalog # CAS Formula Unit
sc-205239 1242-67-7 C23H34O2 1 mg/10 mg
Copper(II) Protoporphyrin IX (free acid)
A negative control for the heme oxygenase inhibitor, zinc protoporphyrin IX.
Catalog # CAS Formula Unit
sc-205935 N/A C34H32CuN4O4 25 mg
(±)-CP 47,497
CP 47,497 is a monophenol cannabimimetic compound that binds the central cannabinoid (CB1) receptor. It is equivalent in analgesic potency to Δ9-THC and exhibits other CB biological activities as well.
Catalog # CAS Formula Unit
sc-205275 70434-82-1 C21H34O2 5 mg/25 mg
(-)-CP 47,497
CP 47,497 is a bicyclic cannabinoid (CB) analog with effective analgesic activity.1 It is comparable or more potent than Δ9-tetrahydrocannabinol in analgesic, motor depressant, anticonvulsant, and hypothermic effects in mice, rats, and dogs.2 The levorotatory enantiomer, (−)-CP 47,497 avidly binds the CB1 receptor (Ki = 2.1 nM).3
Catalog # CAS Formula Unit
sc-205273 114753-51-4 C21H34O2 1 mg/5 mg
(+)-CP 47,497
CP 47,497 is a bicyclic CB analog with potent analgesic activity.1 It is comparable or more potent than Δ9-tetrahydrocannabinol in analgesic, motor depressant, anticonvulsant, and hypothermic effects in mice, rats, and dogs.2 The dextrorotatory enantiomer, (+)-CP 47,497 avidly binds the CB1 (Ki = 4.15 nM).3
Catalog # CAS Formula Unit
sc-205274 134308-14-8 C21H34O2 1 mg/10 mg
(±)-CP 55,940
(±)-CP 55,940 was one of the first bicyclic mimetics of Δ9-THC found to have superior analgesic properties (1,2) The racemic mixture of CP 55,940 is 20-100-fold more effective than Δ9-THC in altering the reactions to mechanical, thermal, and chemical pain in mice (e.g., 50% max possible effect (MPE50) observed in the tail clamp assay at 0.46 and 29.1 mg/kg for (±)-CP 55,940 and Δ9-THC, respectively). CP 55,940 has also been used to characterize and identify the central cannabinoid (CB1) receptor in rat brain membranes. The capacity to displace CP 55,940 from CB1 receptor in rat brain preparations has frequently been used in the characterization of novel cannabimimetics.
Catalog # CAS Formula Unit
sc-223902 83003-12-7 C24H40O3 5 mg/10 mg
CP-55,940
Cannabinoid CB1 and CB2 agonist which is more potent than Δ9-THC. Kd for transfected CB1 and CB2: 2.6 & 3.7 nM. Induces Krox-24 gene expression in corpus striatum and cultured astrocytes.
Catalog # CAS Formula Unit
sc-200359 83002-04-4 C24H40O3 5 mg/25 mg
DEA
Potent endocannabinoid (anandamide analog) that activates CB1 receptors in microglia and binds to rat synaptosomal membranes.
Catalog # CAS Formula Unit
sc-203024 150314-35-5 N/A 5 mg
Decanoyl-p-nitroanilide
Colorimetric substrate for FAAH. Hydrolysis of DepNA by FAAH or by other enzymes releases the yellow p-nitroaniline allowing for the rapid measurement of FAAH activity.
Catalog # CAS Formula Unit
sc-201429 72298-63-6 C16H24N2O3 20 mg/100 mg
Dihomo-γ-linolenylethanolamide
Endocannabinoid. Binds to recombinant human CB1 (Ki=857nM) and CB2 receptor (Ki=598nM). Also inhibits adenylyl cyclase (IC50=109nM).
Catalog # CAS Formula Unit
sc-202137 150314-34-4 C22H39NO2 5 mg
Docosahexaenoyl Ethanolamide
Docosahexaenoic Acid (DHA) is an essential fatty acid and the most abundant ω-3 fatty acid in neural tissues, particularly in the retina and brain. Docosahexaenoyl ethanolamide (DHEA) is an ethanolamine amide of DHA that has been detected in both retina and brain at concentrations similar to those for arachidonoyl ethanolamide (AEA) (1,2). A 9.5 fold increase of DHEA was observed in brain lipid extracts from piglets on a DHA-supplemented diet compared to a DHA-free control diet (3). DHEA binds rat brain CB1 receptor with a Ki of 324 nM, which is about 10-fold higher than the Ki for AEA (4). DHEA inhibits shaker-related voltage-gated potassium channels in the brain slightly better than AEA, with an IC50 of 1.5 µM (5).
Catalog # CAS Formula Unit
sc-221563 162758-94-3 C24H37NO2 5 mg/10 mg
Ethyl Ferulate
Induces heme oxygenase-1 and protects rat neurons against oxidative stress. Protects neurons against amyloid β peptide (1-42)-induced oxidative stress and neurotoxicity.
Catalog # CAS Formula Unit
sc-200823 4046-02-0 N/A 100 mg
Fluprostenol serinol amide
A stable analog of PGF2α 2-glyceryl ester that has much greater stability. The biological activity of Flu-SA has not yet been determined.
Catalog # CAS Formula Unit
sc-221620 N/A C26H36F3NO7 1 mg/5 mg
Glycerophospho-N-Oleoyl Ethanolamine
N-Acylated ethanolamines (NAE) are naturally-occurring lipids with diverse bioactivities. For example, arachidonoyl ethanolamide (AEA) is an endogenous cannabinoid neurotransmitter that evokes cellular responses by activating the cannabinoid receptors, peripheral cannabinoid (CB2) and central cannabinoid (CB1). The different types of NAE are derived from glycerophospho-linked precursors by the activity of glycerophosphodiesterase 1 (GDE1). Glycerophospho-N-oleoyl ethanolamine is the precursor of oleoyl ethanolamide (OEA). OEA is an potent, endogenous agonist for PPARα, exhibiting an EC50 value of 120 nM in a transactivation assay. Systemic administration of OEA suppresses food intake and reduces weight gain in rats (10 mg/kg intraperitoneally) and PPARα wild-type mice, but not in PPARα knockout mice. Like AEA, OEA is metabolized by fatty acid amide hydrolase (FAAH).
Catalog # CAS Formula Unit
sc-224008 201738-24-1 C23H46NO7P 1 mg/5 mg
Glycerophospho-N-Palmitoyl Ethanolamine
N-Acylated ethanolamines (NAE) are naturally-occurring lipids that have diverse bioactivities. For example, arachidonoyl ethanolamide (AEA) is an endogenous neurotransmitter that evokes cellular responses by activating the cannabinoid receptors, peripheral cannabinoid (CB2) and central cannabinoid (CB1). The different types of NAE are derived from glycerophospho-linked precursors by the activity of glycerophosphodiesterase 1 (GDE1). Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is the metabolic precursor of palmitoyl ethanolamide (PEA). PEA is an endogenous CB found in liver, brain, and other mammalian tissues, that has potent anti-inflammatory activity in vivo. PEA has no appreciable affinity for CB1 and low affinity for CB2 suggesting that its efficacy is through a different receptor.
Catalog # CAS Formula Unit
sc-224009 100575-09-5 C21H44NO7P 1 mg/5 mg
GP 1a
Highly selective CB2 agonist receptor; Ki values are 0.037 and 363 nM for CB2 and CB1 receptors respectively. Increases P-ERK1/2 expression in HL-60 cells in vitro.
Catalog # CAS Formula Unit
sc-203980 N/A C23H22Cl2N4O 10 mg/50 mg
GP 2A
Selective CB2 receptor agonist; Ki values are 7.6 and 900 nM for CB2 and CB1 receptors respectively. Increases P-ERK1/2 expression in HL-60 cells in vitro.
Catalog # CAS Formula Unit
sc-203588 919077-81-9 N/A 10 mg/50 mg
GW 842166X
A CB2 receptor agonist with ED50 values of 91 and 63 nM in rat and human, respectively.2 When administered orally to rats in the Freund’s complete adjuvant (FCA) model of inflammatory pain, GW 842166X is highly potent with an ED50 value of 0.1 mg/kg and full reversal of hyperalgesia at 0.3 mg/kg.2
Catalog # CAS Formula Unit
sc-205338 666260-75-9 C18H17Cl2F3N4O2 1 mg/5 mg
HU-331
The endocannabinoids present a rich system of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation.1,2 HU-331 is a hydroxylquinone cannabidiol analog that exhibits potent antineoplastic activity on a variety of human cancer cell lines.3 It inhibits the growth of human Raji and Jurkat lymphoma cells in vitro and has been shown to inhibit the growth of HT-29 colon carcinoma cells.3
Catalog # CAS Formula Unit
sc-205345 137252-25-6 C21H28O3 500 µg/5 mg
IMMA
Selective CB2 receptor ligand.
Catalog # CAS Formula Unit
sc-221749 N/A C23H23N2O4Cl 5 mg
JNJ 1661010
Selective and reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 = 12nM). Brain penetrant and active in vivo.
Catalog # CAS Formula Unit
sc-204023 681136-29-8 C19H19N5OS 10 mg/50 mg
JTE 907
Highly selective cannabinoid CB2 receptor inverse agonist. Binds with high affinity to rat, mouse and human CB2 receptors (Ki values are 0.38, 1.55 and 35.9 nM respectively). Produces anti-inflammatory effects in vivo.
Catalog # CAS Formula Unit
sc-203616 282089-49-0 C24H26N2O6 10 mg/50 mg
JWH 073
JWH 073 is a slightly selective agonist of the CB1 receptor derived from the aminoalkylindole WIN 55,212-2. The Ki values for binding CB1 and the peripheral cannabinoid (CB2) receptor are 8.9 and 38 nM, respectively for a CB1:CB2 ratio of 0.23. Its effects on suppression of spontaneous activity, maximum possible antinociceptive effect in the tail-flick assay, and rectal temperature are comparable to those of WIN 55,212-2 when tested in rats.
Catalog # CAS Formula Unit
sc-224030 208987-48-8 C23H21NO 5 mg/25 mg
JWH 200
JWH 200 is an aminoalkylindole that acts as a cannabinoid (CB) receptor ligand. It binds to the CB1 receptor with high-affinity (IC50 = 7.8-42 nM).1,2 The effects of JWH 200 in locomotor activity, tail-flick latency, hypothermia, and ring-immobility tests are comparable or better than Δ9-THC or WIN-55,212.3 It potently inhibits the contraction of electrically-stimulated murine vas deferens (IC50 = 3.7-6.0 nM).4,5
Catalog # CAS Formula Unit
sc-205357 103610-04-4 C25H24N2O2 5 mg/25 mg
JWH-015
Selective cannabinoid CB2 agonist. (Ki=13.8 and 383nM for CB2 and CB1 receptors respectively).
Catalog # CAS Formula Unit
sc-200367 155471-08-2 C23H21NO 5 mg/25 mg
L-759633
High affinity, selective CB2 receptor agonist. Potently inhibits forskolin-stimulated cAMP production via CB2 receptors expressed in CHO cells.
Catalog # CAS Formula Unit
sc-203438 174627-50-0 C26H40O2 10 mg
Leelamine HCl
Weakly binds the CB1 receptor and does not stimulate G-protein activity. Behavioural changes with treatment are reminiscent of THC treatment and reversed by the CB1 antagonist SR141716A.
Catalog # CAS Formula Unit
sc-200375 1446-61-3 N/A 10 mg/50 mg
Linoleamide
Unsaturated analog of endogenous sleep-inducing lipid.
Catalog # CAS Formula Unit
sc-221852 N/A N/A 10 mg/50 mg
Linoleylethanolamide
Endocannabinoid. Does also bind to TRPV1 (Ki=5.60µM).
Catalog # CAS Formula Unit
sc-203107 68171-52-8 C20H37NO2 5 mg
LY-320135
Potent and selective Canniboid CB1 receptor antagonist/inverse agonist. Selective (~70 fold) over Canniboid CB2 receptors.
Catalog # CAS Formula Unit
sc-204066 176977-56-3 C24H17NO4 10 mg/50 mg
MAFP
Potent, irreversible inhibitor of fatty acid amide hydrolase (FAAH, anandamide amidase), the enzyme responsible for anandamide hydrolysis. Also binds irreversibly to CB1 receptors.
Catalog # CAS Formula Unit
sc-203440 188404-10-6 C21H36FO2P 5 mg
Mead acid ethanolamide
A cannabinoid CB1 and CB2 agonist equipotent with anandamide1.
Catalog # CAS Formula Unit
sc-202704 169232-04-6 C22H39NO2 1 mg/10 mg
N-(3-hydroxyphenyl)-Arachidonoyl amide
An analog of AM404, which is a selective inhibitor of carrier-mediated transport of AEA.1 3-HPA is metabolized by both COX-1 and COX-2 and was found to selectively and irreversibly inhibit COX-2 with an IC50 value of 2 µM.2
Catalog # CAS Formula Unit
sc-221969 183718-75-4 C26H37NO2 5 mg/10 mg
N-Arachidonoyl glycine
Endogenous anandamide-like compound. Lacks affinity for CB1 receptors (Ki>10µM), TRPV1 (EC50>10µM) and anandamide uptake (IC50>50µM), but inhibits fatty acid amide hydrolase (FAAH) (IC50=8.5µM-50µM, depending on cell type and species).
Catalog # CAS Formula Unit
sc-203149 179113-91-8 N/A 5 mg
N-Arachidonoyl phosphatidylethanolamine
N-arachidonoyl phosphatidylethanolamine (NAPE) is a precursor in anandamide (AEA) biosynthesis via multiple pathways. NAPE can be cleaved by a phospholipase D yielding phosphatidic acid and AEA. On the other hand, in macrophages NAPE is cleaved by a phospholipase C yielding phosphoanandamide (pAEA). A phosphatase, PTPN22 is one enzyme that cleaves pAEA leading to the generation of anandamide. Another pathway proceeds via double deacylation of NAPE generating glycerophospho-NAE. Phosphodiesterase-mediated cleavage of this intermediate yields anandamide.
Catalog # CAS Formula Unit
sc-221989 N/A C57H104NO4P 1 mg/5 mg
N-Arachidonoyl-(L)-alanine (NA-Ala)
One member of a new class of lipoamino acids related to anandamide identified in bovine brain (1).
Catalog # CAS Formula Unit
sc-221991 N/A C23H37NO3 5 mg/25 mg
N-Arachidonoyl-GABA (NA-GABA)
One member of a new class of lipoamino acids related to anandamide identified in bovine brain1. Displays analgesic activity1,2.
Catalog # CAS Formula Unit
sc-221992 N/A C24H39NO3 5 mg/25 mg
N-Arachidonoyl-L-serine
Endocannabinoid-like brain constituent with similar biological profile to abnormal cannabidiol. Binds weakly to CB1 and CB2 receptors and TRPV1. Produces endothelium-dependent vasodilation.
Catalog # CAS Formula Unit
sc-202718 187224-29-9 C23H37NO4 10 mg
N-Linoleoylglycine
Possible endogenous LA metabolite and 18:2 anandamide metabolite. May display antinflamatory activity.
Catalog # CAS Formula Unit
sc-205761 2764-03-6 C20H35NO3 5 mg/25 mg
N-Oleoyl-L-serine
N-Oleoylserine was isolated from mouse trabecular bone and brain and was determined to be the L-isomer. It was shown to promote the proliferation and growth of MC3T3 E1 osteoblasts at 10-11M via a pertusis toxin-sensitive mechanism and transiently induced ERK1/2 phosphorylation. It inhibited osteoclast formation in vitro and in an ovariectomy-induced bone loss model, it induced complete rescue after 12 weeks (5mg/kg)1.
Catalog # CAS Formula Unit
sc-222013 N/A N/A 5 mg/25 mg
NESS 0327
NESS 0327 is an extremely potent cannabinoid receptor antagonist with high selectivity for the CB1 receptor compared to the CB2 receptor with Ki values of 0.35 pM and 21 nM, respectively.1 It is a much more potent antagonist and more selective for the CB1 receptor compared to SR 141716A. At nM concentrations NESS 0327 competitively inhibits the binding of the synthetic CB agonist WIN 55,212-2 in isolated rat cerebella membranes and murine vas deferens.1,2 Unlike SR 141716A, NESS 0327 at higher doses does not act as a CB1 receptor inverse agonist and does not produce any physiological effects of its own.1,2
Catalog # CAS Formula Unit
sc-222054 494844-07-4 C24H23Cl3N4O 1 mg/5 mg
NS309
A Ca2+ -activated IK/SK potassium channel activator.
Catalog # CAS Formula Unit
sc-253202 18711-16-5 C8H4Cl2N2O2 5 mg
Noladin ether
Noladin ether is an endogenous agonist of the cannabinoid CB1 receptor and a weak ligand for the CB2 receptor. It causes sedation, hypothermia, intestinal immobility and mild antinociception in mice.
Catalog # CAS Formula Unit
sc-202734 222723-55-9 C23H40O3 1 mg/5 mg
O-1602
Analog of cannabidiol. Antagonist of the endothelial non-CB1/CB2 cannabinoid receptor. Structurally similar to O-1912. Induces endothelium-dependent vasodilation by CB1/CB2/NO-independent mechanism.
Catalog # CAS Formula Unit
sc-202745 317321-41-8 C17H22O2 1 mg/5 mg
O-1821
O-1821 is a cannabidiol analog with close structural similarity to O-1918 which is a selective antagonist of abnormal cannabidiol at the non-CB1/CB2 endothelial receptor.2 O-1918 does not bind to CB1 or CB2 receptors at concentrations up to 30 µM and inhibits the vasorelaxant effects of abnormal cannabidiol in vitro and in whole animals.2 The biological activity of O-1821 has not been reported.
Catalog # CAS Formula Unit
sc-205417 35482-50-9 C17H22O2 1 mg/5 mg
O-1918
Analog of cannabidiol. Antagonist of the endothelial non-CB1/CB2 cannabinoid receptor. Induces endothelium-dependent vasodilation via a CB1/CB2/nitric oxide-independent mechanism.
Catalog # CAS Formula Unit
sc-202746 536697-79-7 C19H26O2 1 mg/5 mg
O-Arachidonoyl Glycidol
2-Arachidonoyl glycerol is an endogenous ligand that binds to both central cannabinoid and peripheral cannabinoid receptors and is involved in the regulation of a broad range of neurotransmitter signaling functions with implications in neurodegenerative diseases, pain, cancer, and obesity.1 Levels of this endocannabinoid are regulated by hydrolysis to glycerol and arachidonic acid by the enzyme monoacylglycerol lipase. O-Arachidonoyl glycidol is a 2-AG analog that blocks 2-oleoyl glycerol hydrolysis in the cytosolic and membrane fractions of rat cerebella with IC50 values of 4.5 and 19 µM, respectively.1 O-Arachidonoyl glycidol inhibits fatty acid amide hydrolase-catalyzed hydrolysis of arachidonoyl ethanolamide in the membrane fraction of rat cerebella with an IC50 value of 12 µM.1
Catalog # CAS Formula Unit
sc-222087 439146-24-4 C23H36O3 5 mg/10 mg
Oleoyl Ethanolamide-d2
Contains two deuterium atoms at the 11 position. It is intended for use as an internal standard for the quantification of OEA by GC- or LC-mass spectrometry.
Catalog # CAS Formula Unit
sc-222098 N/A C20H37D2NO2 100 µg/500 µg
Palmitoyl-N-isopropylamide
Inhibitor of fatty acid amide hydrolase (FAAH). Displays little binding to CB1 and CB2 receptors.
Catalog # CAS Formula Unit
sc-203177 189939-61-5 C19H39NO 5 mg
Palmitoylethanolamide
Endogenous cannabinoid. Weak ligand of CB1 and CB2 receptors. Inhibits FAAH. Immunosuppressant, anti-inflammatory, anti-nociceptive and anti-convulsant in vivo.
Catalog # CAS Formula Unit
sc-202754 544-31-0 C18H37NO2 10 mg
Palmitylethanolamide
An inactive negative control for anandamide at CB1 receptors1. Endogenous agonist at the CB2 receptor2.
Catalog # CAS Formula Unit
sc-205790 544-31-0 C18H37NO2 10 mg/50 mg
Petromyzonol
Petromyzonol is a tetrahydroxy stearol which serves as the primary spawning pheromone in adult sea lamprey. It is produced in the bile of sea lamprey larvae from the bile acid precursor allocholic acid. While the adult sea lamprey is relatively insensitive to petromyzonol itself, the C-24 sulfate ester (petromyzonol sulfate) is a spawning chemoattractant and a pheromone which can be detected at very low concentrations by lamprey olfactory chemoreceptors. Petromyzonol, allocholic acid and petromyzonol sulfate are all found in water samples from fresh water streams bearing larval lamprey populations.1
Catalog # CAS Formula Unit
sc-205430 28979-29-5 C24H42O4 1 mg/5 mg
PF 750
Irreversible fatty acid amide hydrolase (FAAH) inhibitor (IC50 = 16.2 nM) that displays no activity at a range of other serine hydrolases. Orally active and selectively inhibits FAAH within the central nervous system.
Catalog # CAS Formula Unit
sc-204181 959151-50-9 C22H23N3O 10 mg/50 mg
PF-622
Is a potent, irreversible, time-dependent FAAH inhibitor with IC50 values 0.99 and 0.033 µM when preincubated with human recombinant FAAH for 5 and 60 minutes, respectively.1 Activity-based profiling of various human and murine tissue proteome samples showed that it is highly selective for FAAH relative to other serine hydrolases, showing no discernable off-site activity up to 500 µM.1
Catalog # CAS Formula Unit
sc-205431 898235-65-9 C21H22N4O 500 µg/1 mg
Pravadoline
Pravadoline is a novel analgesic agent whose mechanism of action includes inhibition of cyclooxygenase and cannabinoid receptor agonist activity.
Catalog # CAS Formula Unit
sc-200369 92623-83-1 C23H26N2O3 5 mg/25 mg
R-1 Methanandamide Phosphate
The first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB1 and CB2) as Δ9-THC.1,2 A number of related endocannabinoids have been isolated, most notably 2-arachidonoyl glycerol (2-AG).2 The phosphate ester of R-1 methanandamide, R-1MAP, has been tested as a water soluble prodrug analog of AEA.3 The activity of R-1MAP was essentially equivalent to that of AEA in the growth inhibition of C6 glioma cells. However, when tested for inhibition of AEA binding to isolated rat brain CB1 receptors, arachidonoyl ethanolamide phosphate (AEA-P) is about 5-fold less potent as an agonist with a Ki of about 200 nM.4 The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA), but, the effects of R-1MAP on the various LPA receptors have not been tested.
Catalog # CAS Formula Unit
sc-222232 N/A C23H40NO5P 1 mg/5 mg
R-2 Methanandamide
A cannabinoid analog with a methyl group in the (R) configuration at C-2 of the ethanolamine group. In contrast to the other methyl-anandamide analogs, R-2 methanandamide is not an amidohydrolase inhibitor and is nearly as susceptible to amide hydrolysis as AEA itself.1
Catalog # CAS Formula Unit
sc-205968 N/A C23H39NO2 5 mg
(R)-Methanandamide
Potent analog of anandamide with improved metabolic stability and selectivity for the CB1 receptor. Inhibits motor behavior resembling the effects of THC rather than anandamide.
Catalog # CAS Formula Unit
sc-200792 157182-49-5 C23H39NO2 5 mg/25 mg
Rimonabant
Rimonabant, also known as SR141716, was the first selective central cannabinoid (CB1) receptor inverse agonist (Ki = 1.8 nM) to be developed as an appetite suppressant, anti-obesity drug.1 It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects. In rodent models and clinical trials, rimonabant effectively induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.2 However, rimonabant reportedly produces adverse psychiatric and neurological effects (e.g., depression or anxiety) and therefore is not approved by the FDA for use as a weight control medication.2 Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.3
Catalog # CAS Formula Unit
sc-205491 168273-06-1 N/A 5 mg/10 mg
(R,S)-AM1241
Selective CB2 cannabinoid receptor agonist
Catalog # CAS Formula Unit
sc-253349 444912-48-5 C22H22IN3O3 5 mg
(S)-SLV 319
Central cannabinoid receptor antagonists may have potential in the treatment of a number of diseases such as neuro-inflammatory disorders, cognitive disorders, septic shock, obesity, psychosis, addiction, and gastrointestinal disorders. (S)-SLV 319 is a strong and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and CB2, respectively. (S)-SLV 319 is less lipophilic and therefore more water soluble than other known CB1 receptor ligands.
Catalog # CAS Formula Unit
sc-222285 464213-10-3 C23H20Cl2N4O2S 1 mg/5 mg
(±)-SLV 319
(±)-SLV 319 is the mixture of the CB1 receptor antagonist SLV 319 and its distomer, SLV 319 (+)-enantiomer. SLV 319 is a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and CB2, respectively. SLV 319 is less lipophilic and therefore more water soluble than other known CB1 receptor ligands.
Catalog # CAS Formula Unit
sc-222317 362519-49-1 C23H20Cl2N4O2S 1 mg/5 mg
SR 144528
SR 144528 is a selective peripheral cannabinoid receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.1,2 SR 144528 antagonizes the inhibitory effects of CP 55,940 on forskolin-induced adenylyl cyclase activity in CHO cells expressing hCB2.1 SR 144528 has also been used to investigate the contribution of the CB2 receptor in the control of pain initiation as well as suppression of inflammation and immune activation.3,4,5,6
Catalog # CAS Formula Unit
sc-224292 192703-06-3 C29H34ClN3O 5 mg/10 mg
Tetrahydrocannabinol-7-oic Acid
Non-psychoactive metabolite of tetrahydrocannabinol with potent bronchodilatory, anti-inflammatory and analgesic activity. Indirectly antagonizes the actions of PAF. Inhibits leukocyte adhesion.
Catalog # CAS Formula Unit
sc-201033 39690-06-7 C21H28O4 1 mg/5 mg
UCM 707
Potent and selective anandamide uptake inhibitor. Potentiates hypokinetic and antinociceptive effects of anandamide in vivo.
Catalog # CAS Formula Unit
sc-203308 390824-20-1 C25H37NO2 5 mg
URB447
URB447 is a mixed central cannabinoid (CB1) receptor antagonist/peripheral cannabinoid (CB2) receptor agonist with IC50 values of 313 and 41 nM, respectively. At 20 mg/kg delivered intraperitoneally to ob/ob mice and Swiss mice, URB447 reduces food intake and body-weight gain with an efficacy comparable to rimonabant,1 which is an inverse agonist for the CB1. Marketed as an anti-obesity drug and appetite suppressant, rimonabant was subsequently suspended from distribution due to serious psychiatric side effects attributed to its indiscriminate activity on CB1 receptors in the central nervous system (CNS). Unlike rimonabant, URB447 does not penetrate the blood brain barrier (to antagonize CB1 receptors in the CNS); instead, it appears to selectively block peripheral CB1 receptors such as those located in the gastrointestinal tract.
Catalog # CAS Formula Unit
sc-224347 1132922-57-6 C25H21ClN2O 5 mg/10 mg
Virodhamine
Endogenous cannabinoid receptor mixed antagonist/agonist found in higher concentrations peripherally than anandamide. Full agonist at GPR55 and CB2 and partial antagonist/agonist at CB1 (EC50 values are 12, 381 and 2920 nM at GPR55, CB2 and CB1 receptors respectively). Induces hypothermia in vivo.
Catalog # CAS Formula Unit
sc-204383 287937-12-6 C22H37NO2 5 mg/25 mg
Virodhamine hydrochloride
Partial agonist with in vivo antagonist activity at the CB1 receptor (EC50=1.9µM; 61% efficacy), full agonist for the CB2 receptor (100% efficacy).
Catalog # CAS Formula Unit
sc-202853 443129-35-9 N/A 5 mg
WIN 55,212-2
Potent cannabinoid receptor agonist. Potent analgesic in a rat model of neuropathic pain. Activates p42 and p44 MAP kinase via receptor-mediated signaling.
Catalog # CAS Formula Unit
sc-200361 131543-23-2 N/A 10 mg/50 mg
WIN 55,212-3 mesylate
Novel, low potency CB2 receptor silent antagonist and partial CB1 inverse agonist receptor. Competitively antagonizes effects of CP 55,940 (pA2 = 6.1) and SR 144528 (pEC50 = 5.3) at CB2 receptors and acts as a partial inverse agonist at CB1 receptors (pIC50 = 5.5). Displays modest activity at human melatonin MT1 and muscarinic M4 receptors, but is selective over several other GPCRs.
Catalog # CAS Formula Unit
sc-204397 131543-25-4 N/A 10 mg/50 mg
WWL70
A selective inhibitor of α/β-Hydrolase domain 6.1
Catalog # CAS Formula Unit
sc-222420 947669-91-2 C27H23N3O3 1 mg/5 mg
Zinc Protoporphyrin-9
Potent, selective inhibitor of heme oxygenase. Blocks CO biosynthesis and thereby lowers cGMP concentrations in olfactory neuronal cultures.
Catalog # CAS Formula Unit
sc-200329 15442-64-5 N/A 20 mg/100 mg
1,3-bis(4-Bromophenyl)-5-phenyl-2,4-imidazolidinedione
Potent and selective inverse agonist of CB1 receptor (Ki=243nM and EC50=195nM).
Catalog # CAS Formula Unit
sc-202872 878533-35-8 C21H14Br2N2O2 5 mg
2-(14,15-Epoxyeicosatrienoyl) Glycerol
An endogenous central cannabinoid (CB1) receptor agonist that is present at relatively high levels in the central nervous system.1,2,3 2-AG is hydrolyzed by the enzyme monoacylglycerol lipase, terminating its biological activity, and metabolism by cyclooxygenase-2 and lipoxygenases has been documented.4,5 The related endocannabinoid, 2-arachidonoyl ethanolamide (AEA), can be metabolized by cytochrome P450 (CYP450) enzymes in human kidney and liver to a number of epoxy-ethanolamide derivatives.6 2-14,15-EG is a novel CYP450 metabolite of 2-AG in the kidney.7 2-14,15-EG is a potent mitogen for renal epithelial cells, increasing DNA synthesis in LLCPKcl4 cells at concentrations as low as 100 nM and doubling cell proliferation rates at 1 µM.7 In these cells, 2-14,15-EG activates the metalloprotease ADAM17, which cleaves proTGF-α and releases TGF-α as a ligand that initiates the EGFR-ERK signalling pathway.
Catalog # CAS Formula Unit
sc-205073 848667-56-1 C23H38O5 25 µg/50 µg
2-Arachidonoylglycerol (2-AG)
May contain up to 20% of the isomer 1-arachidonoylglycerol. 2-AG is the intrinsic physiological ligand for the cannabinoid CB1 receptor.
Catalog # CAS Formula Unit
sc-200794 53847-30-6 C23H38O4 5 mg
2-Palmitoylglycerol
Endogenous fatty acid glycerol ester that enhances activity of 2-arachidonylglycerol. Does not bind to CB1 or CB2 cannabinoid receptors, but potentiates the apparent binding of 2-AG and increases its ability to inhibit adenylyl cyclase. Enhances in vivo cannabinoid effects of 2-AG following combined administration with 2-linoleoylglycerol.
Catalog # CAS Formula Unit
sc-203465 23470-00-0 C19H38O4 10 mg
3-decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone
A reversible competitive inhibitor of FAAH activity exhibiting an IC50 value of 1.3 µM.2 Has no affinity for the human CB1 receptor and acts as a competitive inhibitor of FAAH activity without being hydrolyzed by the enzyme.2
Catalog # CAS Formula Unit
sc-204619 875014-22-5 C25H32N2OS 500 µg/1 mg
5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-rel-phenol
This chemical is a bicyclic cannabinoid analog that avidly binds the central cannabinoid receptor CB2 (Ki = 0.83 nM) and shows high antinociceptive activity It is ten-fold more potent than Δ9-tetrahydrocannabinol in motor depressant, analgesic, anticonvulsant, and hypothermic effects in mice.
Catalog # CAS Formula Unit
sc-223681 70434-92-3 C22H36O2 5 mg/10 mg
8-iso Prostaglandin F2α Ethanolamide
Its been reported that anandamide (AEA) can be used directly by cyclooxygenase-2 and specific prostaglandin H2 (PGH2) isomerases to produce ethanolamide congeners of the classical PGs, including PGF2α. PGF2α ethanolamide has also been reported to be biosynthesized by this mechanism when AEA was infused into the lung and liver of fatty acid amide hydrolase-deficient mice. The accumulation of AEA can also lead to isoprostane-type peroxidative decomposition. 8-iso PGF2α ethanolamide is a standard that allows one to distinguish these non-enzymatic decomposition products from “prostamides” that possible have enzymatic origin.
Catalog # CAS Formula Unit
sc-221140 N/A C22H39NO5 100 µg/500 µg
ABN-CBD
Neurobehaviorally inactive cannabinoid that acts as a selective agonist for GPR55 (EC50 values are 2.5, >30 and >30 μM at GPR55, CB1 and CB2 receptors respectively). Increases the phosphorylation of protein kinases in, and migration of, human umbilical vein endothelial cells.
Catalog # CAS Formula Unit
sc-203488 22972-55-0 C21H30O2 10 mg
Abnormal Cannabidiol-d3
Contains three deuterium atoms at the terminal methyl position. Intended for use as an internal standard for the quantification of compound by GC- or LC-mass spectrometry. A synthetic regioisomer of cannabidiol that fails to elicit either CB1 or CB2 responsiveness and is without psychotropic activity. Induces endothelium-dependent vasodilation via a CB1/CB2/nitric oxide-independent mechanism.2 Showed hypotensive activity that could not be antagonized by cannabidiol or SR141716A. Compound is therefore believed to activate a third type of CB receptor, provisionally called the non-CB1/CB2 endocannabinoid receptor. Also acts via these receptors to regulate the migratory activity of murine BV-2 microglial cells, with an EC50 value of 600 nM.3
Catalog # CAS Formula Unit
sc-223766 N/A C21H30D3O2 100 µg/500 µg
ACEA
Potent and highly selective CB1 receptor agonist. Displays > 1400-fold selectivity over CB2 receptors. Active in vivo.
Catalog # CAS Formula Unit
sc-202902 220556-69-4 C22H36ClNO 5 mg
Allopregnanolone
Progesterone metabolite devoid of any progestational activity. Acts as a potent ligand of GABA-mediated Cl uptake in synaptosomes more effectively (100- to 1,000-fold) than benzodiazepines or barbituates. In dose-dependent manner, causes a raid increase in Ca2+ influx.
Catalog # CAS Formula Unit
sc-203813 516-54-1 C21H34O2 10 mg
α-Linolenoyl Ethanolamide
α-Linolenoyl ethanolamide is an endocannabinoid containing α-linolenic acid in place of the arachidonate moiety of AEA. It has been detected in porcine brain, but its relative importance and specific role as a cannabinergic neurotransmitter have not been elucidated.
Catalog # CAS Formula Unit
sc-223763 57086-93-8 C20H35NO2 5 mg/10 mg
AM 1241
This is a potent and selective CB2 receptor agonist (Ki=3.4nM (mouse), Ki=280nM (rat) also in vivo.
Catalog # CAS Formula Unit
sc-221241 N/A C22H22N3O3I 1 mg/5 mg
AM 281
Analog of the cannabinoid receptor (CB) antagonist SR 141716A. Potent CB1 receptor antagonist/inverse agonist (Ki=14nM).
Catalog # CAS Formula Unit
sc-202050 202463-68-1 C21H19Cl2IN4O2 1 mg/5 mg
AM-251
Cannabinoid CB1 receptor antagonist (Ki=7.5 nM). Displays a high level of selectivity (306-fold) for CB1 over CB2 receptors.
Catalog # CAS Formula Unit
sc-200366 183232-66-8 C22H21Cl2IN4O 10 mg
AM-404
Anandamide transport inhibitor (IC50=1 µM). Does not activate cannabinoid receptors or inhibit anandamide amidase.
Catalog # CAS Formula Unit
sc-200363 198022-70-7 C26H37NO2 10 mg/50 mg
AM-630
Acts as a cannabinoid receptor antagonist in mouse brain, vas deferens and guinea pig brain, but an agonist in guinea pig ileum. Acts as an inverse agonist on cloned human CB1 receptors.
Catalog # CAS Formula Unit
sc-200365 164178-33-0 C23H25IN2O3 10 mg
AM1241
A peripheral cannabinoid (CB2) receptor agonist with a Ki value of 2 nM and a greater than 100-fold selectivity over the central cannabinoid (CB1) receptor in vitro.1 This molecule produces antinociception to thermal stimuli in rat hindpaw. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630 but not by the CB1 receptor-selective antagonist AM251.1
Catalog # CAS Formula Unit
sc-221242 N/A N/A 1 mg/5 mg
Anandamide (18:2, n-6)
Anandamide analog.1
Catalog # CAS Formula Unit
sc-205592 N/A C20H37NO2 5 mg/25 mg
Anandamide (20:3, n-6)
Endogenous cannabinoid ligand1. Inhibits the binding of [3H]HU-243 to synaptosomal membranes (Ki=53 nM)2.
Catalog # CAS Formula Unit
sc-205593 N/A C22H39NO2 5 mg/25 mg
Anandamide (22:4, n-6)
This compound is an endogenous cannabinoid ligand, 1,2 which inhibits the binding of [3H]HU-243 to synaptosomal membranes (Ki=34 nM)2.
Catalog # CAS Formula Unit
sc-221252 N/A N/A 5 mg/25 mg
Arachidonamide (20:4, n-6)
A weak cannabinoid CB1 and CB2 agonist 1.
Catalog # CAS Formula Unit
sc-221258 N/A N/A 10 mg/50 mg
Arachidonoyl 2'-fluoroethylamide
CB1 receptor agonist (CB1: Ki=26.7nM; CB2: Ki=908nM).
Catalog # CAS Formula Unit
sc-202469 166100-37-4 C22H36NOF 5 mg
Arachidonoyl Ethanolamide Phosphate
Since its isolation and characterization, a number of related endocannabinoids have been isolated, among them 2-arachidonoyl glycerol (2-AG).2 The phosphate ester of AEA, AEA-P, has been tested as a water soluble prodrug version of AEA in the treatment of C6 glioma cells in vivo, acting with essentially the same potency as AEA.3 However, when tested for inhibition of AEA binding to isolated rat brain CB1 receptors, AEA-P is about 5-fold less potent as an agonist.4 The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA) but the effects of AEA-P on the various LPA receptors have not been tested.
Catalog # CAS Formula Unit
sc-205210 183323-26-4 C22H38NO5P 250 µg/1 mg
Arachidonoyl Ethanolamide-d4
Contains four deuterium atoms at the hydroxyethyl 1,1',2, and 2' positions. Used as an internal standard for the quantification of AEA by GC- or LC-mass spectrometry.
Catalog # CAS Formula Unit
sc-221262 N/A C22H33D4NO2 500 µg/1 mg
Arachidonoyl p-Nitroaniline
One of many nitroaniline fatty acid amides used to measure FAAH activity. 1 This is a relatively unselective enzyme that accepts a variety of amide head groups other than the ethanolamine of its nominal endogenous substrate AEA. Has also been shown to hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Has the potential for fast and convenient measurement of FAAH activity using a 96-well plate spectrophotometer: exposure of ApNA to FAAH activity results in the release of p-nitroaniline.
Catalog # CAS Formula Unit
sc-205211 119520-58-0 C26H36N2O3 1 g/10 g
Arachidonoyl-1-thio-Glycerol
2-Arachidonoyl glycerol (2-AG) is an endogenous agonist of the central cannabinoid (CB1) receptor.1,2 It is present at relatively high levels in the central nervous system and is the most abundant molecular species of monoacylglycerol found in rat brain.2,3 Monoacylglycerol lipase (MGL) hydrolyzes 2-AG to arachidonic acid and glycerol, thereby terminating its biological actions.4 Arachidonoyl-1-thio-glycerol is a thioester substrate analog of 2-AG that can be utilized for the measurement of MGL activity.5 Hydrolysis of the thioester bond by MGL generates a free thiol that reacts rapidly with the chromogenic reagent DTNB (Ellman’s reagent) resulting a yellow product with an absorbance maximum at 412 nm.
Catalog # CAS Formula Unit
sc-221265 N/A C23H38O3S 1 mg/5 mg
Arachidonoyl-AMC
A fluorogenic substrate for fatty acid amide hydrolase (FAAH)1. This substrate is the basis for a simple, selective and sensitive assay for FAAH which is amenable to high-throughput screening.
Catalog # CAS Formula Unit
sc-223784 N/A N/A 5 mg/25 mg
Arachidonoyl-N-methyl amide
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. This compound is an analog of AEA that binds to the human CB1 receptor with a Ki of 60 nM.1 It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 µM.2
Catalog # CAS Formula Unit
sc-205212 156910-29-1 C21H35NO 5 mg/10 mg
Arachidonylcyclopropylamide (ACPA)
High affinity selective agonist for the cannbinoid CB1 receptor. Inhibits forskolin-induced cAMP accumulation, increases binding of GTPγS to cerebellar membranes.
Catalog # CAS Formula Unit
sc-200795 229021-64-1 C23H37NO 10 mg/50 mg
AVE-1625
The central cannabinoid (CB1) receptor is a G protein-coupled receptor that is widespread in the central nervous system and several peripheral tissues and binds the active component of cannabis, Δ9-tetrahydrocannabinol. Signaling through the CB1 receptor is involved in attentional and working memory deficits as well as obesity. AVE-1625 is a selective, highly potent antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM. At 1-3 mg/kg, AVE-1625 significantly enhances the performance of rodents in working memory tasks. At 30 mg/kg, AVE-1625 reduces caloric intake by more than 50% of controls, reduces hepatic glycogen levels in rodents and significantly increases lipolysis from fat tissues.
Catalog # CAS Formula Unit
sc-221277 358970-97-5 C23H20Cl2F2N2O2S 1 mg/5 mg
BML-190
A selective and potent ligand for the human cannabinoid CB2 receptor, it acts as an inverse agonist. Inhibits LPS-induced COX2 induction and LPS-induced monocytic cell neurotoxicity.
Catalog # CAS Formula Unit
sc-203533 2854-32-2 C23H23ClN2O4 10 mg/50 mg
CAY10448
An iodinated nonivamide, a potent capsaicin receptor antagonist with an IC50 of approximately 10 nM.3
Catalog # CAS Formula Unit
sc-223862 N/A C18H28INO3 1 mg/5 mg
CB 13
Potent, orally active CB1/CB2 receptor agonist with limited brain penetration (EC50 values are 6.1 and 27.9 nM for CB1 and CB2 receptors respectively). Displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects.
Catalog # CAS Formula Unit
sc-203870 432047-72-8 C26H24O2 10 mg/50 mg
CB-25
CB-25 is a stable analog of anandamide (AEA) and Δ9-tetrahydrocannabinol (THC). It exhibits high affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with Ki values of 5.2 and 13 nM, respectively. CB-25 behaves as an inverse agonist for the CB1 receptor as assessed in a cyclic AMP (cAMP) functional assay.1,2
Catalog # CAS Formula Unit
sc-204675 869376-63-6 C25H41NO3 1 mg/5 mg
CB-52
A stable analog of Δ9-tetrahydrocannabinol (THC) and anandamide (AEA) which exhibits high affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptor with Ki values of 210 and 30 nM, respectively.1 This compound behaves primarily as a CB1 receptor partial agonist and a CB2 receptor neutral antagonist in vitro.2
Catalog # CAS Formula Unit
sc-221404 N/A C26H43NO3 1 mg/5 mg
CBDD
Non-heme iron-containing dioxygenases that catalyze the oxidation of polyunsaturated fatty acids, generating unsaturated fatty acid hyperoxides1, with immediate products of 15-LO fatty acid oxidation acting as mediators in inflammation, thrombosis, and cancer.2 CBDD is a cannabidiol derivative that both potently and selectively inhibits 15-LO.3
Catalog # CAS Formula Unit
sc-205239 1242-67-7 C23H34O2 1 mg/10 mg
Copper(II) Protoporphyrin IX (free acid)
A negative control for the heme oxygenase inhibitor, zinc protoporphyrin IX.
Catalog # CAS Formula Unit
sc-205935 N/A C34H32CuN4O4 25 mg
(±)-CP 47,497
CP 47,497 is a monophenol cannabimimetic compound that binds the central cannabinoid (CB1) receptor. It is equivalent in analgesic potency to Δ9-THC and exhibits other CB biological activities as well.
Catalog # CAS Formula Unit
sc-205275 70434-82-1 C21H34O2 5 mg/25 mg
(-)-CP 47,497
CP 47,497 is a bicyclic cannabinoid (CB) analog with effective analgesic activity.1 It is comparable or more potent than Δ9-tetrahydrocannabinol in analgesic, motor depressant, anticonvulsant, and hypothermic effects in mice, rats, and dogs.2 The levorotatory enantiomer, (−)-CP 47,497 avidly binds the CB1 receptor (Ki = 2.1 nM).3
Catalog # CAS Formula Unit
sc-205273 114753-51-4 C21H34O2 1 mg/5 mg
(+)-CP 47,497
CP 47,497 is a bicyclic CB analog with potent analgesic activity.1 It is comparable or more potent than Δ9-tetrahydrocannabinol in analgesic, motor depressant, anticonvulsant, and hypothermic effects in mice, rats, and dogs.2 The dextrorotatory enantiomer, (+)-CP 47,497 avidly binds the CB1 (Ki = 4.15 nM).3
Catalog # CAS Formula Unit
sc-205274 134308-14-8 C21H34O2 1 mg/10 mg
(±)-CP 55,940
(±)-CP 55,940 was one of the first bicyclic mimetics of Δ9-THC found to have superior analgesic properties (1,2) The racemic mixture of CP 55,940 is 20-100-fold more effective than Δ9-THC in altering the reactions to mechanical, thermal, and chemical pain in mice (e.g., 50% max possible effect (MPE50) observed in the tail clamp assay at 0.46 and 29.1 mg/kg for (±)-CP 55,940 and Δ9-THC, respectively). CP 55,940 has also been used to characterize and identify the central cannabinoid (CB1) receptor in rat brain membranes. The capacity to displace CP 55,940 from CB1 receptor in rat brain preparations has frequently been used in the characterization of novel cannabimimetics.
Catalog # CAS Formula Unit
sc-223902 83003-12-7 C24H40O3 5 mg/10 mg
CP-55,940
Cannabinoid CB1 and CB2 agonist which is more potent than Δ9-THC. Kd for transfected CB1 and CB2: 2.6 & 3.7 nM. Induces Krox-24 gene expression in corpus striatum and cultured astrocytes.
Catalog # CAS Formula Unit
sc-200359 83002-04-4 C24H40O3 5 mg/25 mg
DEA
Potent endocannabinoid (anandamide analog) that activates CB1 receptors in microglia and binds to rat synaptosomal membranes.
Catalog # CAS Formula Unit
sc-203024 150314-35-5 N/A 5 mg
Decanoyl-p-nitroanilide
Colorimetric substrate for FAAH. Hydrolysis of DepNA by FAAH or by other enzymes releases the yellow p-nitroaniline allowing for the rapid measurement of FAAH activity.
Catalog # CAS Formula Unit
sc-201429 72298-63-6 C16H24N2O3 20 mg/100 mg
Dihomo-γ-linolenylethanolamide
Endocannabinoid. Binds to recombinant human CB1 (Ki=857nM) and CB2 receptor (Ki=598nM). Also inhibits adenylyl cyclase (IC50=109nM).
Catalog # CAS Formula Unit
sc-202137 150314-34-4 C22H39NO2 5 mg
Docosahexaenoyl Ethanolamide
Docosahexaenoic Acid (DHA) is an essential fatty acid and the most abundant ω-3 fatty acid in neural tissues, particularly in the retina and brain. Docosahexaenoyl ethanolamide (DHEA) is an ethanolamine amide of DHA that has been detected in both retina and brain at concentrations similar to those for arachidonoyl ethanolamide (AEA) (1,2). A 9.5 fold increase of DHEA was observed in brain lipid extracts from piglets on a DHA-supplemented diet compared to a DHA-free control diet (3). DHEA binds rat brain CB1 receptor with a Ki of 324 nM, which is about 10-fold higher than the Ki for AEA (4). DHEA inhibits shaker-related voltage-gated potassium channels in the brain slightly better than AEA, with an IC50 of 1.5 µM (5).
Catalog # CAS Formula Unit
sc-221563 162758-94-3 C24H37NO2 5 mg/10 mg
Ethyl Ferulate
Induces heme oxygenase-1 and protects rat neurons against oxidative stress. Protects neurons against amyloid β peptide (1-42)-induced oxidative stress and neurotoxicity.
Catalog # CAS Formula Unit
sc-200823 4046-02-0 N/A 100 mg
Fluprostenol serinol amide
A stable analog of PGF2α 2-glyceryl ester that has much greater stability. The biological activity of Flu-SA has not yet been determined.
Catalog # CAS Formula Unit
sc-221620 N/A C26H36F3NO7 1 mg/5 mg
Glycerophospho-N-Oleoyl Ethanolamine
N-Acylated ethanolamines (NAE) are naturally-occurring lipids with diverse bioactivities. For example, arachidonoyl ethanolamide (AEA) is an endogenous cannabinoid neurotransmitter that evokes cellular responses by activating the cannabinoid receptors, peripheral cannabinoid (CB2) and central cannabinoid (CB1). The different types of NAE are derived from glycerophospho-linked precursors by the activity of glycerophosphodiesterase 1 (GDE1). Glycerophospho-N-oleoyl ethanolamine is the precursor of oleoyl ethanolamide (OEA). OEA is an potent, endogenous agonist for PPARα, exhibiting an EC50 value of 120 nM in a transactivation assay. Systemic administration of OEA suppresses food intake and reduces weight gain in rats (10 mg/kg intraperitoneally) and PPARα wild-type mice, but not in PPARα knockout mice. Like AEA, OEA is metabolized by fatty acid amide hydrolase (FAAH).
Catalog # CAS Formula Unit
sc-224008 201738-24-1 C23H46NO7P 1 mg/5 mg
Glycerophospho-N-Palmitoyl Ethanolamine
N-Acylated ethanolamines (NAE) are naturally-occurring lipids that have diverse bioactivities. For example, arachidonoyl ethanolamide (AEA) is an endogenous neurotransmitter that evokes cellular responses by activating the cannabinoid receptors, peripheral cannabinoid (CB2) and central cannabinoid (CB1). The different types of NAE are derived from glycerophospho-linked precursors by the activity of glycerophosphodiesterase 1 (GDE1). Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is the metabolic precursor of palmitoyl ethanolamide (PEA). PEA is an endogenous CB found in liver, brain, and other mammalian tissues, that has potent anti-inflammatory activity in vivo. PEA has no appreciable affinity for CB1 and low affinity for CB2 suggesting that its efficacy is through a different receptor.
Catalog # CAS Formula Unit
sc-224009 100575-09-5 C21H44NO7P 1 mg/5 mg
GP 1a
Highly selective CB2 agonist receptor; Ki values are 0.037 and 363 nM for CB2 and CB1 receptors respectively. Increases P-ERK1/2 expression in HL-60 cells in vitro.
Catalog # CAS Formula Unit
sc-203980 N/A C23H22Cl2N4O 10 mg/50 mg
GP 2A
Selective CB2 receptor agonist; Ki values are 7.6 and 900 nM for CB2 and CB1 receptors respectively. Increases P-ERK1/2 expression in HL-60 cells in vitro.
Catalog # CAS Formula Unit
sc-203588 919077-81-9 N/A 10 mg/50 mg
GW 842166X
A CB2 receptor agonist with ED50 values of 91 and 63 nM in rat and human, respectively.2 When administered orally to rats in the Freund’s complete adjuvant (FCA) model of inflammatory pain, GW 842166X is highly potent with an ED50 value of 0.1 mg/kg and full reversal of hyperalgesia at 0.3 mg/kg.2
Catalog # CAS Formula Unit
sc-205338 666260-75-9 C18H17Cl2F3N4O2 1 mg/5 mg
HU-331
The endocannabinoids present a rich system of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation.1,2 HU-331 is a hydroxylquinone cannabidiol analog that exhibits potent antineoplastic activity on a variety of human cancer cell lines.3 It inhibits the growth of human Raji and Jurkat lymphoma cells in vitro and has been shown to inhibit the growth of HT-29 colon carcinoma cells.3
Catalog # CAS Formula Unit
sc-205345 137252-25-6 C21H28O3 500 µg/5 mg
IMMA
Selective CB2 receptor ligand.
Catalog # CAS Formula Unit
sc-221749 N/A C23H23N2O4Cl 5 mg
JNJ 1661010
Selective and reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 = 12nM). Brain penetrant and active in vivo.
Catalog # CAS Formula Unit
sc-204023 681136-29-8 C19H19N5OS 10 mg/50 mg
JTE 907
Highly selective cannabinoid CB2 receptor inverse agonist. Binds with high affinity to rat, mouse and human CB2 receptors (Ki values are 0.38, 1.55 and 35.9 nM respectively). Produces anti-inflammatory effects in vivo.
Catalog # CAS Formula Unit
sc-203616 282089-49-0 C24H26N2O6 10 mg/50 mg
JWH 073
JWH 073 is a slightly selective agonist of the CB1 receptor derived from the aminoalkylindole WIN 55,212-2. The Ki values for binding CB1 and the peripheral cannabinoid (CB2) receptor are 8.9 and 38 nM, respectively for a CB1:CB2 ratio of 0.23. Its effects on suppression of spontaneous activity, maximum possible antinociceptive effect in the tail-flick assay, and rectal temperature are comparable to those of WIN 55,212-2 when tested in rats.
Catalog # CAS Formula Unit
sc-224030 208987-48-8 C23H21NO 5 mg/25 mg
JWH 200
JWH 200 is an aminoalkylindole that acts as a cannabinoid (CB) receptor ligand. It binds to the CB1 receptor with high-affinity (IC50 = 7.8-42 nM).1,2 The effects of JWH 200 in locomotor activity, tail-flick latency, hypothermia, and ring-immobility tests are comparable or better than Δ9-THC or WIN-55,212.3 It potently inhibits the contraction of electrically-stimulated murine vas deferens (IC50 = 3.7-6.0 nM).4,5
Catalog # CAS Formula Unit
sc-205357 103610-04-4 C25H24N2O2 5 mg/25 mg
JWH-015
Selective cannabinoid CB2 agonist. (Ki=13.8 and 383nM for CB2 and CB1 receptors respectively).
Catalog # CAS Formula Unit
sc-200367 155471-08-2 C23H21NO 5 mg/25 mg
L-759633
High affinity, selective CB2 receptor agonist. Potently inhibits forskolin-stimulated cAMP production via CB2 receptors expressed in CHO cells.
Catalog # CAS Formula Unit
sc-203438 174627-50-0 C26H40O2 10 mg
Leelamine HCl
Weakly binds the CB1 receptor and does not stimulate G-protein activity. Behavioural changes with treatment are reminiscent of THC treatment and reversed by the CB1 antagonist SR141716A.
Catalog # CAS Formula Unit
sc-200375 1446-61-3 N/A 10 mg/50 mg
Linoleamide
Unsaturated analog of endogenous sleep-inducing lipid.
Catalog # CAS Formula Unit
sc-221852 N/A N/A 10 mg/50 mg
Linoleylethanolamide
Endocannabinoid. Does also bind to TRPV1 (Ki=5.60µM).
Catalog # CAS Formula Unit
sc-203107 68171-52-8 C20H37NO2 5 mg
LY-320135
Potent and selective Canniboid CB1 receptor antagonist/inverse agonist. Selective (~70 fold) over Canniboid CB2 receptors.
Catalog # CAS Formula Unit
sc-204066 176977-56-3 C24H17NO4 10 mg/50 mg
MAFP
Potent, irreversible inhibitor of fatty acid amide hydrolase (FAAH, anandamide amidase), the enzyme responsible for anandamide hydrolysis. Also binds irreversibly to CB1 receptors.
Catalog # CAS Formula Unit
sc-203440 188404-10-6 C21H36FO2P 5 mg
Mead acid ethanolamide
A cannabinoid CB1 and CB2 agonist equipotent with anandamide1.
Catalog # CAS Formula Unit
sc-202704 169232-04-6 C22H39NO2 1 mg/10 mg
N-(3-hydroxyphenyl)-Arachidonoyl amide
An analog of AM404, which is a selective inhibitor of carrier-mediated transport of AEA.1 3-HPA is metabolized by both COX-1 and COX-2 and was found to selectively and irreversibly inhibit COX-2 with an IC50 value of 2 µM.2
Catalog # CAS Formula Unit
sc-221969 183718-75-4 C26H37NO2 5 mg/10 mg
N-Arachidonoyl glycine
Endogenous anandamide-like compound. Lacks affinity for CB1 receptors (Ki>10µM), TRPV1 (EC50>10µM) and anandamide uptake (IC50>50µM), but inhibits fatty acid amide hydrolase (FAAH) (IC50=8.5µM-50µM, depending on cell type and species).
Catalog # CAS Formula Unit
sc-203149 179113-91-8 N/A 5 mg
N-Arachidonoyl phosphatidylethanolamine
N-arachidonoyl phosphatidylethanolamine (NAPE) is a precursor in anandamide (AEA) biosynthesis via multiple pathways. NAPE can be cleaved by a phospholipase D yielding phosphatidic acid and AEA. On the other hand, in macrophages NAPE is cleaved by a phospholipase C yielding phosphoanandamide (pAEA). A phosphatase, PTPN22 is one enzyme that cleaves pAEA leading to the generation of anandamide. Another pathway proceeds via double deacylation of NAPE generating glycerophospho-NAE. Phosphodiesterase-mediated cleavage of this intermediate yields anandamide.
Catalog # CAS Formula Unit
sc-221989 N/A C57H104NO4P 1 mg/5 mg
N-Arachidonoyl-(L)-alanine (NA-Ala)
One member of a new class of lipoamino acids related to anandamide identified in bovine brain (1).
Catalog # CAS Formula Unit
sc-221991 N/A C23H37NO3 5 mg/25 mg
N-Arachidonoyl-GABA (NA-GABA)
One member of a new class of lipoamino acids related to anandamide identified in bovine brain1. Displays analgesic activity1,2.
Catalog # CAS Formula Unit
sc-221992 N/A C24H39NO3 5 mg/25 mg
N-Arachidonoyl-L-serine
Endocannabinoid-like brain constituent with similar biological profile to abnormal cannabidiol. Binds weakly to CB1 and CB2 receptors and TRPV1. Produces endothelium-dependent vasodilation.
Catalog # CAS Formula Unit
sc-202718 187224-29-9 C23H37NO4 10 mg
N-Linoleoylglycine
Possible endogenous LA metabolite and 18:2 anandamide metabolite. May display antinflamatory activity.
Catalog # CAS Formula Unit
sc-205761 2764-03-6 C20H35NO3 5 mg/25 mg
N-Oleoyl-L-serine
N-Oleoylserine was isolated from mouse trabecular bone and brain and was determined to be the L-isomer. It was shown to promote the proliferation and growth of MC3T3 E1 osteoblasts at 10-11M via a pertusis toxin-sensitive mechanism and transiently induced ERK1/2 phosphorylation. It inhibited osteoclast formation in vitro and in an ovariectomy-induced bone loss model, it induced complete rescue after 12 weeks (5mg/kg)1.
Catalog # CAS Formula Unit
sc-222013 N/A N/A 5 mg/25 mg
NESS 0327
NESS 0327 is an extremely potent cannabinoid receptor antagonist with high selectivity for the CB1 receptor compared to the CB2 receptor with Ki values of 0.35 pM and 21 nM, respectively.1 It is a much more potent antagonist and more selective for the CB1 receptor compared to SR 141716A. At nM concentrations NESS 0327 competitively inhibits the binding of the synthetic CB agonist WIN 55,212-2 in isolated rat cerebella membranes and murine vas deferens.1,2 Unlike SR 141716A, NESS 0327 at higher doses does not act as a CB1 receptor inverse agonist and does not produce any physiological effects of its own.1,2
Catalog # CAS Formula Unit
sc-222054 494844-07-4 C24H23Cl3N4O 1 mg/5 mg
NS309
A Ca2+ -activated IK/SK potassium channel activator.
Catalog # CAS Formula Unit
sc-253202 18711-16-5 C8H4Cl2N2O2 5 mg
Noladin ether
Noladin ether is an endogenous agonist of the cannabinoid CB1 receptor and a weak ligand for the CB2 receptor. It causes sedation, hypothermia, intestinal immobility and mild antinociception in mice.
Catalog # CAS Formula Unit
sc-202734 222723-55-9 C23H40O3 1 mg/5 mg
O-1602
Analog of cannabidiol. Antagonist of the endothelial non-CB1/CB2 cannabinoid receptor. Structurally similar to O-1912. Induces endothelium-dependent vasodilation by CB1/CB2/NO-independent mechanism.
Catalog # CAS Formula Unit
sc-202745 317321-41-8 C17H22O2 1 mg/5 mg
O-1821
O-1821 is a cannabidiol analog with close structural similarity to O-1918 which is a selective antagonist of abnormal cannabidiol at the non-CB1/CB2 endothelial receptor.2 O-1918 does not bind to CB1 or CB2 receptors at concentrations up to 30 µM and inhibits the vasorelaxant effects of abnormal cannabidiol in vitro and in whole animals.2 The biological activity of O-1821 has not been reported.
Catalog # CAS Formula Unit
sc-205417 35482-50-9 C17H22O2 1 mg/5 mg
O-1918
Analog of cannabidiol. Antagonist of the endothelial non-CB1/CB2 cannabinoid receptor. Induces endothelium-dependent vasodilation via a CB1/CB2/nitric oxide-independent mechanism.
Catalog # CAS Formula Unit
sc-202746 536697-79-7 C19H26O2 1 mg/5 mg
O-Arachidonoyl Glycidol
2-Arachidonoyl glycerol is an endogenous ligand that binds to both central cannabinoid and peripheral cannabinoid receptors and is involved in the regulation of a broad range of neurotransmitter signaling functions with implications in neurodegenerative diseases, pain, cancer, and obesity.1 Levels of this endocannabinoid are regulated by hydrolysis to glycerol and arachidonic acid by the enzyme monoacylglycerol lipase. O-Arachidonoyl glycidol is a 2-AG analog that blocks 2-oleoyl glycerol hydrolysis in the cytosolic and membrane fractions of rat cerebella with IC50 values of 4.5 and 19 µM, respectively.1 O-Arachidonoyl glycidol inhibits fatty acid amide hydrolase-catalyzed hydrolysis of arachidonoyl ethanolamide in the membrane fraction of rat cerebella with an IC50 value of 12 µM.1
Catalog # CAS Formula Unit
sc-222087 439146-24-4 C23H36O3 5 mg/10 mg
Oleoyl Ethanolamide-d2
Contains two deuterium atoms at the 11 position. It is intended for use as an internal standard for the quantification of OEA by GC- or LC-mass spectrometry.
Catalog # CAS Formula Unit
sc-222098 N/A C20H37D2NO2 100 µg/500 µg
Palmitoyl-N-isopropylamide
Inhibitor of fatty acid amide hydrolase (FAAH). Displays little binding to CB1 and CB2 receptors.
Catalog # CAS Formula Unit
sc-203177 189939-61-5 C19H39NO 5 mg
Palmitoylethanolamide
Endogenous cannabinoid. Weak ligand of CB1 and CB2 receptors. Inhibits FAAH. Immunosuppressant, anti-inflammatory, anti-nociceptive and anti-convulsant in vivo.
Catalog # CAS Formula Unit
sc-202754 544-31-0 C18H37NO2 10 mg
Palmitylethanolamide
An inactive negative control for anandamide at CB1 receptors1. Endogenous agonist at the CB2 receptor2.
Catalog # CAS Formula Unit
sc-205790 544-31-0 C18H37NO2 10 mg/50 mg
Petromyzonol
Petromyzonol is a tetrahydroxy stearol which serves as the primary spawning pheromone in adult sea lamprey. It is produced in the bile of sea lamprey larvae from the bile acid precursor allocholic acid. While the adult sea lamprey is relatively insensitive to petromyzonol itself, the C-24 sulfate ester (petromyzonol sulfate) is a spawning chemoattractant and a pheromone which can be detected at very low concentrations by lamprey olfactory chemoreceptors. Petromyzonol, allocholic acid and petromyzonol sulfate are all found in water samples from fresh water streams bearing larval lamprey populations.1
Catalog # CAS Formula Unit
sc-205430 28979-29-5 C24H42O4 1 mg/5 mg
PF 750
Irreversible fatty acid amide hydrolase (FAAH) inhibitor (IC50 = 16.2 nM) that displays no activity at a range of other serine hydrolases. Orally active and selectively inhibits FAAH within the central nervous system.
Catalog # CAS Formula Unit
sc-204181 959151-50-9 C22H23N3O 10 mg/50 mg
PF-622
Is a potent, irreversible, time-dependent FAAH inhibitor with IC50 values 0.99 and 0.033 µM when preincubated with human recombinant FAAH for 5 and 60 minutes, respectively.1 Activity-based profiling of various human and murine tissue proteome samples showed that it is highly selective for FAAH relative to other serine hydrolases, showing no discernable off-site activity up to 500 µM.1
Catalog # CAS Formula Unit
sc-205431 898235-65-9 C21H22N4O 500 µg/1 mg
Pravadoline
Pravadoline is a novel analgesic agent whose mechanism of action includes inhibition of cyclooxygenase and cannabinoid receptor agonist activity.
Catalog # CAS Formula Unit
sc-200369 92623-83-1 C23H26N2O3 5 mg/25 mg
R-1 Methanandamide Phosphate
The first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB1 and CB2) as Δ9-THC.1,2 A number of related endocannabinoids have been isolated, most notably 2-arachidonoyl glycerol (2-AG).2 The phosphate ester of R-1 methanandamide, R-1MAP, has been tested as a water soluble prodrug analog of AEA.3 The activity of R-1MAP was essentially equivalent to that of AEA in the growth inhibition of C6 glioma cells. However, when tested for inhibition of AEA binding to isolated rat brain CB1 receptors, arachidonoyl ethanolamide phosphate (AEA-P) is about 5-fold less potent as an agonist with a Ki of about 200 nM.4 The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA), but, the effects of R-1MAP on the various LPA receptors have not been tested.
Catalog # CAS Formula Unit
sc-222232 N/A C23H40NO5P 1 mg/5 mg
R-2 Methanandamide
A cannabinoid analog with a methyl group in the (R) configuration at C-2 of the ethanolamine group. In contrast to the other methyl-anandamide analogs, R-2 methanandamide is not an amidohydrolase inhibitor and is nearly as susceptible to amide hydrolysis as AEA itself.1
Catalog # CAS Formula Unit
sc-205968 N/A C23H39NO2 5 mg
(R)-Methanandamide
Potent analog of anandamide with improved metabolic stability and selectivity for the CB1 receptor. Inhibits motor behavior resembling the effects of THC rather than anandamide.
Catalog # CAS Formula Unit
sc-200792 157182-49-5 C23H39NO2 5 mg/25 mg
Rimonabant
Rimonabant, also known as SR141716, was the first selective central cannabinoid (CB1) receptor inverse agonist (Ki = 1.8 nM) to be developed as an appetite suppressant, anti-obesity drug.1 It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects. In rodent models and clinical trials, rimonabant effectively induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.2 However, rimonabant reportedly produces adverse psychiatric and neurological effects (e.g., depression or anxiety) and therefore is not approved by the FDA for use as a weight control medication.2 Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.3
Catalog # CAS Formula Unit
sc-205491 168273-06-1 N/A 5 mg/10 mg
(R,S)-AM1241
Selective CB2 cannabinoid receptor agonist
Catalog # CAS Formula Unit
sc-253349 444912-48-5 C22H22IN3O3 5 mg
(S)-SLV 319
Central cannabinoid receptor antagonists may have potential in the treatment of a number of diseases such as neuro-inflammatory disorders, cognitive disorders, septic shock, obesity, psychosis, addiction, and gastrointestinal disorders. (S)-SLV 319 is a strong and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and CB2, respectively. (S)-SLV 319 is less lipophilic and therefore more water soluble than other known CB1 receptor ligands.
Catalog # CAS Formula Unit
sc-222285 464213-10-3 C23H20Cl2N4O2S 1 mg/5 mg
(±)-SLV 319
(±)-SLV 319 is the mixture of the CB1 receptor antagonist SLV 319 and its distomer, SLV 319 (+)-enantiomer. SLV 319 is a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and CB2, respectively. SLV 319 is less lipophilic and therefore more water soluble than other known CB1 receptor ligands.
Catalog # CAS Formula Unit
sc-222317 362519-49-1 C23H20Cl2N4O2S 1 mg/5 mg
SR 144528
SR 144528 is a selective peripheral cannabinoid receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.1,2 SR 144528 antagonizes the inhibitory effects of CP 55,940 on forskolin-induced adenylyl cyclase activity in CHO cells expressing hCB2.1 SR 144528 has also been used to investigate the contribution of the CB2 receptor in the control of pain initiation as well as suppression of inflammation and immune activation.3,4,5,6
Catalog # CAS Formula Unit
sc-224292 192703-06-3 C29H34ClN3O 5 mg/10 mg
Tetrahydrocannabinol-7-oic Acid
Non-psychoactive metabolite of tetrahydrocannabinol with potent bronchodilatory, anti-inflammatory and analgesic activity. Indirectly antagonizes the actions of PAF. Inhibits leukocyte adhesion.
Catalog # CAS Formula Unit
sc-201033 39690-06-7 C21H28O4 1 mg/5 mg
UCM 707
Potent and selective anandamide uptake inhibitor. Potentiates hypokinetic and antinociceptive effects of anandamide in vivo.
Catalog # CAS Formula Unit
sc-203308 390824-20-1 C25H37NO2 5 mg
URB447
URB447 is a mixed central cannabinoid (CB1) receptor antagonist/peripheral cannabinoid (CB2) receptor agonist with IC50 values of 313 and 41 nM, respectively. At 20 mg/kg delivered intraperitoneally to ob/ob mice and Swiss mice, URB447 reduces food intake and body-weight gain with an efficacy comparable to rimonabant,1 which is an inverse agonist for the CB1. Marketed as an anti-obesity drug and appetite suppressant, rimonabant was subsequently suspended from distribution due to serious psychiatric side effects attributed to its indiscriminate activity on CB1 receptors in the central nervous system (CNS). Unlike rimonabant, URB447 does not penetrate the blood brain barrier (to antagonize CB1 receptors in the CNS); instead, it appears to selectively block peripheral CB1 receptors such as those located in the gastrointestinal tract.
Catalog # CAS Formula Unit
sc-224347 1132922-57-6 C25H21ClN2O 5 mg/10 mg
Virodhamine
Endogenous cannabinoid receptor mixed antagonist/agonist found in higher concentrations peripherally than anandamide. Full agonist at GPR55 and CB2 and partial antagonist/agonist at CB1 (EC50 values are 12, 381 and 2920 nM at GPR55, CB2 and CB1 receptors respectively). Induces hypothermia in vivo.
Catalog # CAS Formula Unit
sc-204383 287937-12-6 C22H37NO2 5 mg/25 mg
Virodhamine hydrochloride
Partial agonist with in vivo antagonist activity at the CB1 receptor (EC50=1.9µM; 61% efficacy), full agonist for the CB2 receptor (100% efficacy).
Catalog # CAS Formula Unit
sc-202853 443129-35-9 N/A 5 mg
WIN 55,212-2
Potent cannabinoid receptor agonist. Potent analgesic in a rat model of neuropathic pain. Activates p42 and p44 MAP kinase via receptor-mediated signaling.
Catalog # CAS Formula Unit
sc-200361 131543-23-2 N/A 10 mg/50 mg
WIN 55,212-3 mesylate
Novel, low potency CB2 receptor silent antagonist and partial CB1 inverse agonist receptor. Competitively antagonizes effects of CP 55,940 (pA2 = 6.1) and SR 144528 (pEC50 = 5.3) at CB2 receptors and acts as a partial inverse agonist at CB1 receptors (pIC50 = 5.5). Displays modest activity at human melatonin MT1 and muscarinic M4 receptors, but is selective over several other GPCRs.
Catalog # CAS Formula Unit
sc-204397 131543-25-4 N/A 10 mg/50 mg
WWL70
A selective inhibitor of α/β-Hydrolase domain 6.1
Catalog # CAS Formula Unit
sc-222420 947669-91-2 C27H23N3O3 1 mg/5 mg
Zinc Protoporphyrin-9
Potent, selective inhibitor of heme oxygenase. Blocks CO biosynthesis and thereby lowers cGMP concentrations in olfactory neuronal cultures.
Catalog # CAS Formula Unit
sc-200329 15442-64-5 N/A 20 mg/100 mg
MescalitoBandito
Bluelighter
Wow, I had no idea there were so many identified already. Anything more potent than 018 could really get annoying.
I just found my gram of 018 after misplacing it for a few weeks. I kind of miss having 073 to mix in with it but I was never able to find anything but yellowish, smelly 073, whereas it's easy to get very pure 018 in my experience.
I also agree that foil is the best way to smoke it, once you figure out the finer details. I've smoked quite a bit of fentanyl and tar dope in my day, so it comes naturally to me 8).
I actually created a little mini-spoon by breaking a pair of tweezers in half. I find that the tip of it holds up to 5mg depending on density, so I like to just scoop up a tiny little bit and try to see how little I can get away with. I think it should be noted that even though eyeballing is inherently risky (especially at this dose), I feel more comfortable with the estimation system I've worked out. My scale has trouble with weighing under 3mg, and I doubt it's accurate enough to tell me the difference between 1 and 2mg anyway.
I just found my gram of 018 after misplacing it for a few weeks. I kind of miss having 073 to mix in with it but I was never able to find anything but yellowish, smelly 073, whereas it's easy to get very pure 018 in my experience.
I also agree that foil is the best way to smoke it, once you figure out the finer details. I've smoked quite a bit of fentanyl and tar dope in my day, so it comes naturally to me 8).
I actually created a little mini-spoon by breaking a pair of tweezers in half. I find that the tip of it holds up to 5mg depending on density, so I like to just scoop up a tiny little bit and try to see how little I can get away with. I think it should be noted that even though eyeballing is inherently risky (especially at this dose), I feel more comfortable with the estimation system I've worked out. My scale has trouble with weighing under 3mg, and I doubt it's accurate enough to tell me the difference between 1 and 2mg anyway.
Oxymorphone
Bluelighter
- Joined
- May 20, 2008
- Messages
- 1,258
I have some JWH-018 coming. I haven't smoked weed in a couple years and now I get drug tested so I can't risk it being in my system. With synthetics it is really appealing since they don't show up on tests. How similar is it to actual good cannabis?
- Status